Evome Medical Technologies (Evome Medical Technologies) Return-on-Tangible-Equity : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Evome Medical Technologies Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Evome Medical Technologies's annualized net income for the quarter that ended in Dec. 2023 was $-47.15 Mil. Evome Medical Technologies's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-6.07 Mil. Therefore, Evome Medical Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Evome Medical Technologies's Return-on-Tangible-Equity or its related term are showing as below:

LNDZF's Return-on-Tangible-Equity is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.67
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Evome Medical Technologies Return-on-Tangible-Equity Historical Data

The historical data trend for Evome Medical Technologies's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evome Medical Technologies Return-on-Tangible-Equity Chart

Evome Medical Technologies Annual Data

Trend

Dec14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Dec23

Return-on-Tangible-Equity

Get a 7-Day Free Trial

-6.26

-18.52

-55.64

-287.27

Evome Medical Technologies Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Mar23	Jun23	Sep23	Dec23
Return-on-Tangible-Equity	Get a 7-Day Free Trial															-	-	-	Negative Tangible Equity	-

Competitive Comparison of Evome Medical Technologies's Return-on-Tangible-Equity

For the Medical Devices subindustry, Evome Medical Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evome Medical Technologies's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Evome Medical Technologies's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Evome Medical Technologies's Return-on-Tangible-Equity falls into.

Evome Medical Technologies Return-on-Tangible-Equity Calculation

Evome Medical Technologies's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(A: Dec. 2023 )		(A: Feb. 2022 )		(A: Dec. 2023 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets )	/ count )
		(A: Dec. 2023 )		(A: Feb. 2022 )		(A: Dec. 2023 )
	=	-11.63	/	( (-2.837	+	-7.02 )	/ 2 )
	=	-11.63	/	-4.9285
	=	N/A %

Evome Medical Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-47.148	/	( (-5.129	+	-7.02)	/ 2 )
	=	-47.148	/	-6.0745
	=	N/A %

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

Evome Medical Technologies (OTCPK:LNDZF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Evome Medical Technologies Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Evome Medical Technologies's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.